MedReleaf

MedReleaf is a branded line of standardized medical cannabis products developed originally by MedReleaf Corp (later acquired by Aurora Cannabis) and supplied in markets such as Canada and Australia as dried flower, oils, capsules, and other dosage forms with defined tetrahydrocannabinol (THC) and cannabidiol (CBD) potencies. These products act primarily through activation or modulation of the endocannabinoid system via cannabinoid receptors CB1 and CB2, leading to downstream effects on pain signaling, inflammation, mood, appetite, sleep, and other neurological and immune pathways, and are used under medical supervision for conditions such as chronic pain, sleep disturbances and various mental health or quality-of-life symptoms. MedReleaf-branded products are produced under pharmaceutical-style quality controls, with strain-specific and formulation-specific offerings, and are positioned as prescription medical cannabis rather than over-the-counter supplements.

Brand names

MedReleaf